Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile

Seminars in Neurology

Volumn 36, Issue 1, 2016, Pages 29-33

  Dashtipour, Khashayar ^a   Pedouim, Farzin ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

AbobotulinumtoxinA; IncobotulinumtoxinA; OnabotulinumtoxinA; RimabotulinumtoxinB

Indexed keywords

BOTULINUM TOXIN;

ARTICLE; BLEPHARITIS; BOTULISM; CELLULITIS; CLINICAL TRIAL (TOPIC); DIPLOPIA; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG STORAGE; DRUG USE; DYSPHAGIA; ECCHYMOSIS; FATIGUE; FLU LIKE SYNDROME; FOLLICULITIS; HEMATOMA; HUMAN; IMMUNOGENICITY; INJECTION SITE BLEEDING; INJECTION SITE PAIN; LIMB WEAKNESS; MEDICATION ERROR; MUSCLE WEAKNESS; NONHUMAN; PRIORITY JOURNAL; PTOSIS; XEROSTOMIA; ANIMAL; ANTIBODY PRODUCTION; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOGENETICS; IMMUNOLOGY; MIGRAINE DISORDERS; PAIN;

ANIMALS; ANTIBODY FORMATION; BOTULINUM TOXINS; DRUG COMPOUNDING; HUMANS; IMMUNOGENETIC PHENOMENA; MIGRAINE DISORDERS; MUSCLE WEAKNESS; PAIN;

EID: 84958185509     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0035-1571213     Document Type: Article

References (21)

1. Pellett S. Learning from the past: historical aspects of bacterial toxins as pharmaceuticals. Curr Opin Microbiol: 2012; 15 3 292 299
2. Dressler D., Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil: 2007; 29 23 1761 1768
3. Setler P. E. Therapeutic use of botulinum toxins: background and history. Clin J Pain: 2002; 18 (6, Suppl) S119 S124
4. Wortzman M. S., Pickett A. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthet Surg J: 2009; 29 (6, Suppl) S34 S42
5. BOTOX (onabotulinumtoxinA) [package insert]. Irvine, CA: Allergan, Inc; 2011
6. Dysport (abobotulinumtoxinA) [package insert]. Wrexham, UK: Ipsen Biopharm, Ltd; 2010
7. XEOMIN (incobotulinumtoxinA) [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2011
8. MYOBLOC (rimabotulinumtoxinB) [package insert]. South San Francisco, CA: Solstice Neurosciences, Inc.; 2010
9. 183 Ongoing current clinical trials on botulinum neurotoxin. Available at: https://clinicaltrials.gov/ct2/results?term=botulinum+toxin&recr=Open. Accessed July 7, 2015
10. Naumann M., So Y., Argoff C. E., et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology: 2008; 70 19 1707 1714
11. Naumann M., Dressler D., Hallett M., et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon: 2013; 67 141 152
12. Setler P. The biochemistry of botulinum toxin type B. Neurology: 2000; 55 12 05 S22 S28
13. Ramirez-Castaneda J., Jankovic J., Comella C., Dashtipour K., Fernandez H. H., Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord: 2013; 28 13 1775 1783
14. Carli L., Montecucco C., Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve: 2009; 40 3 374 380
15. Yaraskavitch M., Leonard T., Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech: 2008; 41 4 897 902
16. Chen J. J., Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: A primer. Pharmacotherapy: 2013; 33 3 304 318
17. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D: 2015; 15 1 1 9
18. Naumann M., Boo L. M., Ackerman A. H., Gallagher C. J. Immunogenicity of botulinum toxins. J Neural Transm (Vienna): 2013; 120 2 275 290
19. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs: 2012; 26 2 e1 e9
20. Schulte-Baukloh H., Bigalke H., Miller K., et al. Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure. Int J Urol: 2008; 70 133 136, discussion 415
21. Frevert J., Dressler D. Complexing proteins in botulinum toxin type A drugs: A help or a hindrance? Biologics: 2010; 4 325 332